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 Introduction 
 The central role of macrophage activation in a hemo-
phagocytic syndrome associated with pediatric rheumat-
ic diseases was reported in 1985  [1] , although the first 
descriptions of the disorder may have been as early as the 
mid-1970s  [2, 3] . Subsequent work on the clinical entity 
now known as macrophage activation syndrome (MAS) 
has demonstrated that it may be appropriate to classify 
MAS as a secondary form of hemophagocytic lymphohis-
tiocytosis (HLH). In this review, we will discuss aspects 
of the pathophysiology, diagnosis, and contemporary 
management of MAS/secondary HLH with a focus on as-
sociations with rheumatologic disease, and will accord-
ingly examine the published literature using the MAS 
terminology with forays as appropriate into the literature 
accompanying HLH. 
 Case Definition and Epidemiology  
 MAS is a phenomenon characterized by cytopenia, 
 organ dysfunction, and coagulopathy associated with in-
appropriate activation of macrophages. The current clas-
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sification of MAS is imprecise, however, it is included 
among the reactive hemophagocytic syndromes, and the 
case definition generally proceeds according to the re-
vised diagnostic criteria for HLH ( table 1 )  [4, 5] . The term 
‘macrophage activation syndrome’ was used in a descrip-
tion of the disorder by Albert et al. [6] in 1992 and fur-
thered by Stephan et al. [7, 8] in their 1993 description of 
4 pediatric patients suffering from the disorder as a com-
plication of autoimmune disease characterized by a pro-
inflammatory milieu  [9, 10] . This terminology remains 
prevalent in the rheumatology literature, whereas syn-
dromes described in the hematology and infectious dis-
ease literature often describe a similar phenomenon as 
secondary HLH  [11] . It is now recognized that MAS is a 
form of secondary HLH. Some authors suggest that the 
terms are interchangeable  [12–15] , whereas others de-
scribe MAS as a distinct subset of secondary HLH  [16, 
17] , and still others highlight the heterogeneity of disor-
ders described by both terms and call for revised termi-
nology based more precisely on pathophysiology  [18–20] . 
 Accordingly, the current diagnostic scheme remains a 
work in progress, and several groups have emphasized 
challenges in applying the most recent classification cri-
teria for HLH to MAS. For example, systemic juvenile 
idiopathic arthritis (sJIA) is among the most frequent 
rheumatologic associations with MAS  [20, 21] . However, 
sJIA is independently associated with anemia and hyper-
ferritinemia  [22] in the absence of MAS, and frequently 
is associated with leukocytosis  [23] . Each of these features 
is relevant to the HLH-2004 diagnostic criteria, and the 
overlap in clinical features can contribute to difficulty in 
recognizing the onset of MAS  [24] . Similarly, coagulopa-
thies are common in MAS and other disorders in the dif-
ferential diagnosis for HLH, thereby complicating at-
tempts at obtaining tissue samples for histological diag-
nosis that may even then be prone to sampling error and 
a lack of specificity  [25, 26] .
 To address these concerns and further refine the defi-
nition and classification of the disorder in the subset of 
patients with sJIA-associated MAS, Ravelli et al.  [27]  ex-
amined historical data from 74 patients with presumed 
MAS and 37 control patients with sJIA and high disease 
activity. Using a ‘classification criteria approach’, the au-
thors proposed a set of four laboratory criteria and three 
clinical criteria for the diagnosis of MAS complicating 
sJIA ( table 2 ). In their systemic evaluation, Ravelli et al. 
 [27] also identified a number of characteristic findings on 
routinely available studies that, while not included in the 
formal proposed criteria, are associated with the syn-
drome and may contribute to the index of suspicion ( ta-
ble 3 ). 
 These criteria await prospective validation, and the 
degree to which they might be predictive in MAS associ-
ated with rheumatologic disorders other than MAS is un-
clear. For example, the same group later reported on his-
torical data from pediatric patients suffering from MAS 
Table 1.  2004 Criteria for the diagnosis of HLH [5, 60]
Molecular diagnosis consistent with HLH or five of the eight fol-
lowing criteria
Fever
Splenomegaly
Peripheral cytopenia in 2 or more lineages
Hb <10.0 g/dl (or 9.0 g/dl in infants <4 weeks)
Platelets <100 ! 106/l
Neutrophils <1.0 ! 106/l
Hypertriglyceridemia or hypofibrinogenemia
Triglycerides ≥265 mg/dl
Fibrinogen ≤150 mg/dl
Hemophagocytosis 
Bone marrow
Spleen
Lymph node
CSF
Low or absent NK-cell activity
Ferritin ≥500 g/dl
Soluble CD25 ≥2,400 U/ml
Table 2. Proposed criteria for the diagnosis of MAS complicating 
sJIA (at least two criteria must be fulfilled)
Laboratory criteria Value
Relative decrease in platelet count ≤262 ! 106/l
Elevations in aspartate aminotransferase >59 U/l
Decreased leukocyte count ≤4.0 ! 106/l
Hypofibrinogenemia ≤250 mg/dl
Clinical criteria Manifestation
Central nervous irritability
system dysfunction headache
lethargy
disorientation
seizures
coma
Hemorrhages ecchymoses
purpura
mucosal bleeding
Hepatomegaly ≥3 cm below the costal margin
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associated with systemic lupus erythematosus (SLE). 
They found that while MAS associated with SLE shared 
many clinical characteristics with sJIA-associated MAS, 
the differences were sufficient to render the proposed 
sJIA-associated MAS criteria inapplicable to SLE-associ-
ated MAS  [20] .
 The epidemiology of MAS in autoimmune diseases 
 [28–30] remains an open question in many cases. To date, 
the syndrome has been best studied in sJIAs, with esti-
mates of clinically apparent MAS ranging from 7 to 13% 
 [24, 31] . Furthermore, subclinical marrow evidence of 
MAS was present in  1 50% of patients with sJIA in one 
series  [24] . However, MAS has been reported in a wide 
spectrum of rheumatologic disorders, from the primarily 
pediatric disorder of Kawasaki disease to the seronega-
tive spondyloarthropathies in adults ( table 4 ). 
 Comprehensive published data on MAS in other auto-
immune disorders  [32] are often lacking, and the calcula-
tion of quantitative estimates of the incidence and preva-
lence of MAS is further complicated by an evolving no-
menclature and the heretofore prominent absence of 
clearly defined diagnostic criteria  [14, 20, 23] . In the case 
of sJIA and Still’s disease, it has been proposed that MAS 
is not a distinct disorder but comprises one end of a spec-
trum of disease activity  [24, 33] .
 Pathophysiology 
 Microscopic descriptions of erythrophagocytosis by 
reticular macrophages in hemophagocytic syndromes 
were reported at least as early as 1939  [34] . Despite 70 
years of study, however, the pathophysiology of MAS and 
other hemophagocytic syndromes remains poorly un-
derstood, and much of the understanding of MAS derives 
from the HLH literature  [14] . 
 Overview of Macrophage Activation 
 Not surprisingly, high levels of several T-cell-driven 
macrophage-stimulatory chemokines and cytokines may 
be found in hemophagocytic syndromes, including IFN-
  , MCP-1, and M-CSF  [35–38] . The central role of T cells 
in the hemophagocytic disorders is further illustrated by 
the diagnostic and prognostic significance of elevated se-
rum levels of the IL-2 receptor, CD25  [39] . Conversely, 
elevated levels of several macrophage-driven proinflam-
matory cytokines are present in many cases, including 
IL-6, IL-12, IL-18, and TNF-   [37, 40, 41] , and the pres-
ence of TNF-  and IL-6 expression by CD68+ macro-
phages has been demonstrated in the hepatic parenchy-
ma of patients with hemophagocytic syndromes  [42] . The 
role of IL-1 is less clear in hemophagocytic syndromes, 
being elevated in some cases and normal in others, per-
haps reflecting heterogeneity in the disorders  [37, 43] . 
Striking proliferation of CD163+ hemophagocytic mac-
rophages in marrow and lymphoid tissues is a central fea-
ture of hemophagocytic disorders  [44, 45] . The literature 
suggests that these cells may not be the antigen-present-
ing cells (APCs) responsible for initiating the syndrome 
 [15] . 
 Intriguingly, CD163 is associated with the ‘alternate’ 
pathway of macrophage differentiation, traditionally 
leading to an anti-inflammatory phenotype  [46] . Perhaps 
counterintuitively, a subgroup of patients with sJIA pa-
tients at higher presumed risk for MAS were found to ex-
press higher levels of genes associated with negative feed-
back regulation of inflammation  [47] . The authors specu-
Table 3.  Laboratory features not included among diagnostic cri-
teria characterizing MAS complicating sJIA [27]
Sensitivity Specificity
ESR ≤50 mm/h 0.79 0.8
Alanine aminotransferase ≥40 U/l 0.81 0.91
Bilirubin ≥1.2 mg/dl 0.75 1
Lactate dehydrogenase ≥900 U/l 0.75 0.93
Albumin ≤2.5 g/l 0.35 0.95
Serum sodium ≤130 mEq/l 0.67 1
Table 4.  Autoimmune diseases for which an association with 
MAS has been reported
Autoimmune diseases References
Dermatomyositis 85
Kawasaki disease 44, 86, 87
SLE 20, 44, 57, 86, 88–92
Adult-onset Still’s disease 93
Ankylosing spondylitis 94
Sarcoidosis 95
Inflammatory bowel disease 96, 97
Enthesitis-related arthritis 31
Undefined autoimmune disease 57
Polyarticular JIA 98
sJIA/Still’s disease 8, 14, 15, 31, 33, 40, 44, 50, 
53, 57, 75, 93, 99–109
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late that inflammation initiated by Toll-like receptor 
activation events and characterized by expression of IL-1 
and IL-6 may lead to negative feedback responses that 
direct macrophages to a CD163+ ‘scavenger’ phenotype, 
priming the progression to the clinically apparent hemo-
phagocytic syndromes  [47] . A separate group demon-
strated that the anti-inflammatory molecule HO-1 is 
strongly associated with CD163 expression and hemo-
phagocytosis in macrophages, and may serve a protective 
role in sepsis  [25] . Furthermore, elevated levels of the im-
munomodulatory cytokine IL-10 have been identified in 
patients with HLH  [41] . Taken together, these data beg 
the question of whether CD163+ erythrophagocytic mac-
rophages actually represent an effector arm of a counter-
regulatory response to inflammation in the hemophago-
cytic syndromes  [14, 15] . 
 Natural Killer Cell and Cytotoxic CD8+ T-Cell Defects 
 Studies of patients with familial forms of HLH dem-
onstrated that diminished cytotoxicity of CD8+ T cells as 
well as natural killer (NK) cells were central features of 
those disorders  [48] . Subsequently, single gene defects in 
perforin expression were found to be causative of many 
cases of the familial forms of HLH  [49] . Additionally, re-
cent data have suggested that heterozygotic polymor-
phisms in perforin genes may be associated with the de-
velopment of MAS in patients with coexistent sJIA. At 
least three genes have been identified as causative in fa-
milial HLH, while several monogenic disorders and pri-
mary immunodeficiencies associated with defective cy-
totoxic function may present with hemophagocytic syn-
dromes as a primary manifestation of the underlying 
molecular defect ( table 5 ). 
 Extension of these data to MAS confirmed that dimin-
ished NK-cell activity was strongly associated with the 
development of MAS in sJIA  [18, 19] . Even in the absence 
of clinical MAS, defects in both CD8+ cytotoxic function 
and NK-cell function can distinguish sJIA from other 
rheumatologic syndromes in the JIA classification 
scheme of the International League of Associations for 
Rheumatology that are far less commonly associated 
with MAS  [50, 51] . Interestingly, it has now been recog-
nized that polymorphisms in some of the genes associ-
ated with familial hemophagocytosis syndromes may 
also be associated with the development of MAS in sJIA 
 [52, 53] .
 Current Pathophysiologic Understanding 
 Elucidation of the cytokine milieu associated with he-
mophagocytic syndromes, together with the identifica-
tion of associated defects in T- and NK-cell cytotoxicity, 
have contributed to two models of the pathogenesis of 
MAS. In the first model, defective clearance of infected 
cells leads to ongoing antigen presentation by APCs, lead-
ing to dysregulated activation of T cells and macrophages 
and the subsequent manifestations of the disorder  [54] . In 
the second model, defects in the cytotoxic response result 
in a failure to clear the APCs and activated T cells them-
selves, inducing the persistence of activated immune cells 
that would otherwise be eliminated through cytotoxic 
mechanisms for immune downregulation or tolerance 
 [4, 14, 15, 54, 55] . While there is some evidence for both 
models, no identified infectious trigger can be found in 
many patients. Additionally, the finding that G-CSF 
worsens while cyclosporine improves the syndrome more 
strongly supports the second hypothesis  [54] .
 Additional Clinical Features 
 Recognition of MAS in Rheumatologic Disease 
 The recognition of incipient MAS in patients with 
rheumatologic disease requires a high index of suspicion, 
as several characteristics of the disorder may be shared 
with underlying autoimmune diseases, such as cytopenia 
Table 5.  Established genetic causes for familial HLH
Genetic causes References
Monogenic defects in familial HLH
Perforin mutations 49
Syntaxin-11 110
MUNC13-4 abnormalities 52, 53, 110, 111
Monogenic periodic fever syndromes
CINCA/NOMID syndrome 31
Hyper-IgD syndrome 38
Monogenic primary immunodeficiencies
Griscelli syndrome 112
X-linked lymphoproliferative disease 60, 68
Immunodeficiency, centromeric region
instability, and facial anomalies 113
Adenosine deaminase deficiency 114
Chediak-Higashi syndrome 115
Hermansky-Pudlak syndrome (type II) 116
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and CNS dysfunction in SLE or hyperferritinemia in sJIA 
 [23] . Furthermore, the clinical presentation of MAS may 
strongly resemble overwhelming infection and sepsis, the 
latter of which is both a more common condition and one 
to which patients already on immunosuppressive thera-
pies may be predisposed  [56] . The presence of factors sus-
pected to be associated with MAS ( table 6 ) may provide 
clues to the disorder, but in some cases, no antecedent 
trigger can be identified  [57] . 
 Therefore, while MAS should be considered in the dif-
ferential diagnosis of all patients with rheumatologic dis-
ease and a change in their baseline consistent with the 
clinical features of the disease, the entirety of the indi-
vidual clinical presentation must be taken into account in 
assessing the pretest probability of the disorder. 
 In a large review of 74 sJIA patients by Ravelli et al. 
 [27] , the onset of fever  1 38  °  C was the most common but 
least specific finding. However, the authors comment 
that the specificity data regarding fever may be mislead-
ing, as changes in the fever pattern from the spiking pat-
tern typical of sJIA to the nonremitting pattern of MAS 
may provide additional information to guide the index of 
suspicion. The potential for clinical heterogeneity in the 
disorder is highlighted by the fact that less than a third of 
the patients in this series exhibited detectable lymphade-
nopathy ( table 7 ). 
 Hepatomegaly was present in just over 60% of the pa-
tients with the disorder, with other features such as a cu-
taneous rash, bleeding diatheses, splenomegaly, and CNS 
dysfunction all being present in less than half of the pa-
tients. Stephan et al.  [57] reported on 24 patients with a 
range of rheumatic diseases complicated by MAS, some 
of whom were included in the Ravelli series. Half of the 
children in their series had pulmonary involvement, and 
 1 40% required admission to the intensive care unit. Or-
gan involvement further extended to cardiac dysfunction 
in 42% of patients and renal involvement in 16%. 
 Of the nine possible HLH-2004 criteria for MAS, three 
involve tests (sCD25, NK cell activity assays, and genetic 
testing)  [58, 59] that are unlikely to be rapidly available 
in-house at many institutions, while a fourth requires 
both the ability to undergo an invasive procedure and the 
avoidance of sampling error  [5, 27, 60] . Furthermore, 
even the finding of hemophagocytosis by CD163+ mac-
rophages in marrow and other tissue is not unique to the 
HLH disorders  [25] . Thus, routine testing of all patients 
with rheumatologic disease and a new clinical feature 
(such as fever) for each of the HLH-2004 criteria would 
be cost-ineffective, could confuse the diagnosis if biopsy 
data were misapplied in isolation, and might expose 
many patients to unnecessary risks. Similarly, waiting for 
the delayed results of HLH-2004-directed testing in pa-
Table 6. Presumed precipitating factors in secondary HLH
Precipitating factors References
Medications
Aspirin 57
Non-steroidal anti-inflammatory drugs 1, 117
Sulfasalazine 57
Etanercept 2, 3, 106
Anakinra 74
Gold salts 1, 7, 118
Morniflumate 57
Methotrexate 105, 119, 120
Infliximab 96
Penicillamine 121
Vancomycin 122
Autologous stem cell transplantation 123–125
Parenteral lipid administration 126
Infectious agents
Epstein-Barr virus 57, 127
Cytomegalovirus 18, 19
Varicella virus 57
HHV6 128
Parvovirus B19 57
Hepatitis A 129
HIV/AIDS 33
Adenovirus 130
Coxsackievirus 57
Torovirus 44
Escherichia coli 44
Salmonella 57
Enterococcus 31
Tuberculosis 131
Visceral leishmaniasis 20, 132
Pneumocystis jiroveci 57
Table 7.  Prevalence of clinical features associated with MAS com-
plicating sJIA [1–3, 7, 8, 27, 100, 103, 117, 118, 121, 125, 133–146]
Clinical features Patients
positive, n
Prevalence in
reported analyses
Fever ≥38° C 60 0.81
Hepatomegaly 45 0.61
Cutaneous rash 33 0.45
Splenomegaly 33 0.45
Hemorrhages 29 0.39
CNS dysfunction 28 0.38
Lymphadenopathy 21 0.28
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tients with true MAS prior to initiating therapy could in-
vite catastrophe  [17, 23] , and many patients with true 
MAS may require treatment initiation prior to the fulfill-
ment of strict criteria when clinical suspicion is high  [61] , 
similar to aggressive forms of arthritis  [32, 62] due to nov-
el mechanisms  [63, 64] . Lastly, differences in precipitat-
ing events, diagnostic parameters, and prognostic factors 
between adults and children exist  [65–72] , leading some 
authors to suggest that the current gold standard of the 
HLH-2004 criteria cannot be applied in the adult popula-
tion  [12] . 
 Given the problems of using delayed results to diag-
nose a fulminant disease, together with both the poor 
individual sensitivity and specificity of many of the clin-
ical findings of MAS according to the HLH-2004 criteria, 
certain features on routine laboratories may be of greater 
utility at the bedside in the initial consideration of the 
disorder. Indeed, the proposed Ravelli criteria for MAS 
complicating sJIA use laboratory values that can be 
quickly obtained locally at inpatient institutions with 
reasonably equipped laboratory facilities. However, the 
Ravelli criteria are to date neither validated in sJIA nor 
intended to apply to MAS in other disorders  [20] . Fur-
thermore, the problem of overlap of individual signs and 
symptoms with other rheumatologic conditions remains 
 [27] . 
 Grom  [54]  and others  [23, 57, 73, 74] have suggested 
that the characteristically low erythrocyte sedimentation 
rate (ESR) in MAS may provide a valuable signal to dis-
tinguish the onset of MAS (in which the ESR falls despite 
worsening inflammation) from worsening of inflamma-
tion in other disorders that can be confused with MAS, 
but typically would manifest in the opposite change in 
the ESR. Ferritin, one of the HLH-2004 diagnostic crite-
ria, is widely available in many diagnostic laboratories 
and has been suggested as an inexpensive first step in a 
diagnostic screening strategy capable of being widely ap-
plied to exclude a hemophagocytic syndrome in adult pa-
tients presenting with the systemic inflammatory re-
sponse syndrome  [12] . The authors propose the measure-
ment of serum ferritin as a ‘gateway’ test to guide the 
rational application of more specialized diagnostic pro-
cedures and the rapid administration of therapy  [12, 33, 
75] .
 Treatment Considerations 
 No standard of care yet exists for the diagnosis and 
treatment of MAS in many patients with rheumatologic 
disease  [12, 27] , similar to what is observed in other forms 
of autoimmunity  [76–78] . Case series and individual re-
ports supporting the use of a number of immunosuppres-
sive regimens for hemophagocytic syndromes abound in 
the literature ( table 8 ). 
 Interpretation of the collective data is complicated by 
the fact that a number of the therapies described have also 
been implicated as potential precipitants of the hemo-
phagocytic syndromes ( table 6 ), and the possibility that 
development of presumed drug-related MAS in some pa-
tients may represent insufficient control of the underly-
ing inflammation rather than a true drug-related event 
 [23, 54, 79] .
 In 2002, Henter et al.  [65] published a report demon-
strating an 80% survival rate to hematopoietic stem cell 
transplants compared to approximately 50% survival in 
historical controls using the HLH-94 protocol. Building 
on this experience, the group  [65] recently published 
widely accepted revised diagnostic and therapeutic 
guidelines for the management of children under 18 years 
suffering from any HLH form according to the experi-
mental protocol of the ongoing HLH-2004 study  [5, 60] . 
Notably, their treatment protocol recommends maximal 
supportive care prior to initiation of specific treatment. 
These measures are aggressive, and include the adminis-
tration of empiric oral anti-fungal therapy, prophylactic 
cotrimoxazole, intravenous immunoglobulin, peptic ul-
cer prophylaxis, and, in patients with coexistent viral in-
fections, consideration of specific antiviral therapy. Ther-
apy is initiated and continued for an 8-week tapering 
course, with re-intensification of therapy to week-2 levels 
if reactivation develops ( table 9 ). 
Table 8.  Treatment options proposed for HLH associated with 
autoimmune disease in case series and individual reports
Therapy References
Cyclosporine 7, 8, 31, 57, 147
Etanercept 56, 143
Anakinra 43
Intravenous immunoglobulin 33, 75, 108, 109, 130
Etoposide 5, 60, 67, 71, 100, 148
Plasmapheresis 149
Abatacept 61
Antithymocyte globulin 7, 8, 61
Corticosteroids 7, 8, 12, 150
Naproxen 150
Splenectomy 151
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 If patients respond and there is no evidence of reacti-
vation or a known familial HLH syndrome, a secondary 
form of HLH (such as autoimmune disease-associated 
MAS) is presumed, treatment is discontinued, and close 
follow-up is initiated. Where reactivation occurs or a ge-
netic HLH syndrome is identified, continuation therapy 
is initiated and the patient proceeds to definitive therapy 
with hematopoietic stem cell transplant  [5, 60] .
 However, application of the HLH-2004 protocol to 
secondary forms of HLH such as those due to malignan-
cy or rheumatic disease may be imperfect, and the au-
thors of the HLH-2004 guidelines concede that alternate 
treatment modalities may be required in these scenarios 
 [5, 60] , e.g. as many as half of the patients with MAS sec-
ondary to sJIA may respond to corticosteroids alone  [23, 
24, 57] . Additionally, the clinical features of MAS may 
differ from those seen in other forms of HLH  [17, 31, 80, 
81] , and the features of HLH syndromes in children may 
differ from those in adults  [12] , potentially altering the 
risk/benefit ratio of therapies originally applied to famil-
ial and other forms of HLH.
 In children, some authors have suggested risk stratifi-
cation to guide approaches to initial therapy  [12, 67, 71] . 
Similar data are not extant in adults, however  [12] . Nev-
ertheless, in both children and adults with MAS, some 
authors have advocated an approach centered on aggres-
sive supportive management and high-dose corticoste-
roids as an initial step, followed by second-line therapies 
for refractory disease as indicated, such as cyclosporine 
A, etoposide, and the administration of intravenous 
 immunoglobulin  [12, 23] . A multinational (Canadian/
Swiss/French) group has advocated an approach in adults 
that includes initiation of high-dose corticosteroids, 
elimination of known or suspected triggers, initiation of 
aggressive supportive measures, and infection control, 
with progression in the face of refractory disease to either 
intravenous immunoglobulin (1 g/kg for 2 days) or, in the 
case of malignancy or Epstein-Barr virus infection, either 
cyclosporine A/etoposide or appropriate chemotherapy 
 [12] . In the event of refractory disease despite eventual 
progression to cyclosporine A/etoposide, the suggested 
protocol of Emmenegger et al.  [12] allows for consider-
ation of progression to such therapies as polychemother-
apy, plasma exchange, antithymocyte globulin, splenec-
tomy, or hematopoietic stem cell transplant.
 Conclusions 
 MAS is a form of secondary HLH, the appropriate di-
agnosis and management of which have historically been 
clouded by an imperfect nomenclature and an immature 
but evolving understanding of the underlying pathophys-
iology. The history of the management of MAS associated 
with autoimmune diseases, together with associated 
HLH syndromes such as those that may accompany ma-
Table 9.  The HLH-2004 treatment protocol for the management of familial and secondary HLH in children 
younger than 18 years [5, 60]
Systemic therapy Dexamethasone Etoposide Cyclosporine
Week 1 10 mg/m2 daily 150 mg/m2 i.v. twice weekly 3 mg/kg twice daily
Week 2 10 mg/m2 daily 150 mg/m2 i.v. twice weekly dose to trough 200 g/l
Week 3 5 mg/m2 daily 150 mg/m2 i.v. once weekly dose to trough 200 g/l
Week 4 5 mg/m2 daily 150 mg/m2 i.v. once weekly dose to trough 200 g/l
Week 5 2.5 mg/m2 daily 150 mg/m2 i.v. once weekly dose to trough 200 g/l
Week 6 2.5 mg/m2 daily 150 mg/m2 i.v. once weekly dose to trough 200 g/l
Week 7 1.25 mg/m2 daily 150 mg/m2 i.v. once weekly dose to trough 200 g/l
Week 8 taper and discontinue 150 mg/m2 i.v. once weekly dose to trough 200 g/l
Intrathecal therapya <1 year of age 1–2 years of age 2–3 years of age
Methotrexate 6 mg 8 mg 10 mg
Prednisolone 4 mg 6 mg 8 mg
a  CSF evaluation at diagnosis and after 14 days – if there is clinical neurologic progression or abnormal CSF 
at 2 weeks, intrathecal therapy should be given weekly on days 15, 22, 29, and 36.
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lignancy, primary immunodeficiency, and infection, 
highlight the critical role of the clinical immunologist at 
the juncture of the traditional specialties of hematology/
oncology, allergy/immunology, infectious disease, rheu-
matology, and the subdivisions of adult and pediatric 
medicine thereof  [82] . The modern management of MAS 
and other HLH syndromes has made great strides as a 
result of therapeutic advances over the last 20 years, sim-
ilar to promising approaches to therapies  [83] and etiol-
ogy  [84] in other clinical settings, but the promise of even 
greater strides looms as the benefits of standardized no-
menclature, systematic investigation, and collaborative 
medicine take root in the soil of team-based science. 
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